# BioMarin Pharmaceutical Inc. – Consensus ‘buy’ rating and 25.4% Upside Potential

- Link: https://www.directorstalkinterviews.com/biomarin-pharmaceutical-inc.consensus-buy-rating-and-25.4-upside-potential/4121145965
- Published: 2024-03-04T13:42:17+00:00
- Author: Charlotte Edwards

**BioMarin Pharmaceutical Inc.** which can be found using ticker (BMRN) have now
24 confirmed analysts covering the stock with the consensus suggesting a rating 
of ‘buy’. The target price High/Low ranges between $138.00 and $80.00 and has a 
mean target at $108.21. Given that the stocks previous close was at $86.28 and the
analysts are correct then there would likely be a percentage uptick in value of 
25.4%. The day 50 moving average is $91.99 and the 200 day moving average is $89.76.
The company has a market cap of 16.44B. The stock price for the company is currently
$87.14 USD

 The potential market cap would be $20,620,133,188 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 100.16, revenue per share of $12.88
and a 1.63% return on assets.

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company that develops
and commercializes therapies that address the root cause of genetic conditions. 
The Company’s portfolio consists of seven commercial products and multiple clinical
and preclinical product candidates for the treatment of various diseases. BioMarin’s
commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), 
Kuvan (sapropterin dihydrochloride), Palynziq (pegvaliase-pqpz), Brineura (cerliponase
alfa), Roctavian (valoctocogene roxaparvovec) and Voxzogo (vosoritide). The Roctavian
is an adeno associated virus (AAV5) vector drug development candidate designed to
restore factor VIII plasma concentrations in patients with severe hemophilia A. 
The Company’s clinical development programs include BMN 331, an AAV5 mediated gene
therapy for people living with Hereditary Angioedema (HAE) and BMN 255 is a small-
molecule therapy that is designed to treat hyperoxaluria in chronic liver disease.

Share on:
